TRex Bio, Inc. Prices $116.7M IPO at $14
TRex Bio priced 8.3M shares at $14 each, raising $116.7M in its IPO. Trading begins Oct. 9 on Nasdaq under ticker TRXB. Underwriters have a 30-day option for 1.25M more shares. The company plans to use proceeds for its clinical-stage immunology pipeline.
How this was made
The 30-second read
Why it matters
The IPO pricing and proceeds provide immediate capital for trial advancement, likely attracting speculative interest.
Market read
First‑day pricing of a biotech IPO creates a short‑term trading opportunity and adds a new ticker to the market.
What to watch
Potential dilution from the underwriters' option and the company's cash burn rate could temper enthusiasm.
Background
TRex Bio is a clinical‑stage immunology company debuting on Nasdaq.
Market effects
Adds a new player to the biotech/clinical‑stage immunology space, modestly expanding sector supply.
US biotech IPO pipeline gains visibility; may encourage similar listings.
Limited to investors focused on US biotech IPOs.
Counterpoint
If the pricing is too aggressive, the stock could face immediate sell‑off once lock‑up expires.
Key entities
- companyTRex Bio, Inc.
Biotech firm conducting an IPO on Nasdaq.
